Objective: There is inconsistent evidence that zidovudine use during pregnancy increases overall, cardiac, and male genital malformations.
Introduction
Use of antiretroviral drugs during pregnancy has dramatically reduced the risk of perinatal transmission of HIV to less than 1% [1, 2] . However, there are lingering concerns about the safety of specific antiretroviral agents when used during pregnancy, and careful evaluation of the risks associated with specific drugs is needed to inform treatment decisions. Zidovudine is one antiretroviral agent that is frequently used to treat HIV during pregnancy, though it is no longer a component of the preferred first-line treatment, largely because of programmatic reasons unrelated to safety [3] .
Some epidemiological studies have found that zidovudine use, especially in the first trimester, is associated with modest elevations in the risk of overall malformations [4] , cardiac malformations [5] [6] [7] , and male genital malformations [8, 9] . However, a number of other studies have not replicated the increased risk [10] [11] [12] [13] [14] [15] . There are several potential explanations for these seemingly inconsistent results, including heterogeneity in study design, exposure definition, and outcome measurement. Further, because malformations are rare events, individual studies may lack the power to detect differences in risk, especially for specific malformation subgroups.
To provide more robust estimates of the association between zidovudine and overall, cardiac, and male genital malformations, we used Bayesian methods, which allow us to formally incorporate existing knowledge about an association into an analysis of new data. We conducted a systematic review and meta-analysis to develop a prior distribution for the risk of malformations associated with zidovudine, and incorporated data from the Medicaid Analytic eXtract (MAX) to provide a comprehensive assessment of the evidence available on this safety concern.
Methods

Study population
The study used data from MAX, a collection of enrollment information and health care claims for Medicaid beneficiaries nationwide in the United States. We had access to claims for inpatient and outpatient diagnoses and procedures, as well as outpatient pharmacy dispensing, from 2000 to 2010. An estimated 45% of all deliveries that occur in the United States are covered by Medicaid [16] .
We identified a cohort of pregnancies in MAX, where distinct mothers and infants could be matched. The creation of this cohort has previously been described in detail [17] , and has been used in multiple studies of prescription drug safety during pregnancy [18] [19] [20] [21] . Briefly, women between the ages of 12 and 55 years old with a code indicating a delivery were identified and linked to live-born infants based on shared family case numbers. We removed infants linked to more than one woman, as well as deliveries that were unreasonably close in time. The sample was restricted to women continuously enrolled in Medicaid, without supplementary private insurance or restricted benefits, for 3 months prior to the estimated last menstrual period (LMP) through 30 days after delivery, and infants were required to be continuously enrolled for 90 days after delivery or until death, whichever occurred sooner. We estimated LMP using an algorithm which correctly classifies pregnancy duration within 2 weeks in 99% of term and 75% of preterm deliveries [22] . For infants without diagnosis or procedure codes that indicated prematurity, date of LMP was 270 days prior to the delivery date. For preterm deliveries, date of LMP was 245 days prior to the delivery date. The first trimester was defined as the 90-day period after LMP, the second trimester as the period from 91 to 180 days after LMP, and the third trimester as the period from 181 days after LMP through delivery.
We included women who met any of our diagnostic criteria for HIV infection: at least two claims for an HIV diagnosis; at least one claim for HIV diagnosis and at least one HIV-related procedure; or at least one claim for HIV diagnosis and at least two dispensings of antiretroviral drugs (see Supplemental Digital Content Table S1 for diagnostic and procedure codes, http://links.lww.com/ QAD/B110). We further limited the sample to women who received some form of antiretroviral therapy (ART) during pregnancy, defined by at least one dispensing of an antiretroviral medication between LMP and delivery. We applied this restriction to create a comparative safety study design with an active comparator group, which produces results that are useful for clinical decision-making and less susceptible to confounding by indication [23] .
Exposure and outcome definitions A pregnancy was defined as having zidovudine exposure during the first trimester if at least one prescription for the drug was dispensed during the first trimester. Women in the exposed group were commonly coprescribed other antiretroviral drugs in addition to zidovudine. The comparison group was comprised of pregnancies where the ART received did not include any dispensings of zidovudine during the first trimester.
Infant malformations were identified in the 90-day postdelivery period. An organ system was defined as having a malformation if there were at least two recorded diagnostic codes on separate dates for an anomaly in the organ system (or a diagnostic code and a surgical code), either from maternal or infant records, or one code and a recorded infant death within three months of delivery (see Supplemental Digital Content Table S2 for full list of codes, http://links.lww.com/QAD/B110). In this analysis, we focused on three outcomes: overall malformations from any organ system, cardiac malformations, and male genital malformations. A validation study found that cardiac malformations identified in MAX had a positive predictive value of 78% [24] .
Confounding and adjustment
We considered a variety of risk factors for malformations as potential confounders, including maternal demographic characteristics, markers of HIV disease severity, comorbid medical conditions (including the obstetric comorbidity index) [25] , obstetric characteristics, and prescription drugs. Confounders were defined in the 3-month baseline period prior to LMP and the first trimester.
To adjust for confounding, propensity scores were used to match each exposed pregnancy to an unexposed pregnancy. Propensity scores were calculated using a logistic regression model that estimated the probability of being dispensed zidovudine in the first trimester based on confounder values. All variables listed in Table 2 were included in the propensity score. We performed 1 : 1 fixed-ratio matching using a greedy algorithm [26] , based on the logit transformation of the propensity score. To minimize residual confounding, we used a caliper of 0.2 times the standard deviation of the logit transformation of the propensity score [27] .
Development of a Bayesian prior
Bayesian methods require specification of a prior probability distribution for each parameter included in the model. This prior can be conceptualized as a summary of beliefs about the true value of a variable before considering any new data. In this way, Bayesian analyses allowed us to incorporate existing evidence about zidovudine exposure and risk of congenital malformations into our analysis of the MAX data.
To develop our prior, we conducted a systematic review and meta-analysis for studies that examined the relationship between use of zidovudine in pregnancy and our three outcomes of interest: overall congenital malformation, cardiac malformation, and male genital malformation. We searched MEDLINE via PubMed, EMBASE, and Cochrane CENTRAL for abstracts with terms related to 'zidovudine' and 'pregnancy/congenital malformations.' The references cited in all included studies were reviewed to identify additional eligible articles. Search criteria are described in detail in Supplemental Digital Content Table S3 , http://links. lww.com/QAD/B110.
Articles were included if they were written in English and reported sufficient information to calculate an odds ratio (OR) for zidovudine exposure during pregnancy and one of the outcomes of interest (overall, cardiac, and/or male genital malformation). We excluded conference abstracts, animal studies, basic science research, case reports, case series, and commentaries. When multiple reports were published from the same study, we only included the most recent publication to avoid duplication. In secondary analyses, we further restricted the meta-analysis to studies that defined exposure to zidovudine in the first trimester, had a comparison group that received ART, and controlled for confounding.
Two authors (K.R., J.W.S.) each screened the titles and abstracts of all identified articles according to the inclusion and exclusion criteria listed above. For articles passing the initial screen, the two authors independently performed full text review, finalized inclusion decisions, and extracted the relevant information using a standardized form. All discrepancies were resolved through discussion until reaching a consensus.
A random-effects meta-analysis was performed using the DerSimonian and Laird method [28] to summarize findings and construct a prior, and results were reported in forest plots. The I 2 metric was computed to quantify between-study heterogeneity, and Egger's test was performed to identify publication bias [29, 30] . The meta-analysis was conducted using publically available user-written packages in Stata [31, 32] .
Statistical analysis
The risk of each outcome was summarized in the full and matched MAX samples. Within the matched sample, we used a Bayesian approach to build a logistic model for the risk of malformation from exposure to zidovudine in pregnancy. Separate models were created for each malformation outcome. The prior distributions for the zidovudine-malformation relationships were set according to results of the meta-analysis, and a noninformative prior was specified for the model intercept term. Posterior estimates of the ORs and an accompanying 95% credible interval were developed using Markov Chain Monte Carlo methods. Because malformations are a rare outcome, the estimated OR closely approximates a risk ratio [33, 34] . Bayesian analyses were performed in SAS, version 9.4 (SAS Institute, Cary, North Carolina, USA).
Results
After removing duplicate references, the search strategy identified 4673 unique citations, whose titles and abstracts were screened (Fig. 1 ). After screening, 48 citations underwent a full-text review, and results from 17 articles were included in the meta-analysis [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [35] [36] [37] [38] [39] . For the outcome of overall malformation, 14 articles contributed information on over 27 239 infants with in-utero zidovudine exposure and over 36 501 infants without zidovudine exposure. Seven studies contributed information on cardiac malformations (n ¼ 8956 zidovudine exposed, n ¼ 15 100 unexposed), and five contributed information on male genital malformations (n ¼ 8630 zidovudine exposed, n ¼ 4643 unexposed). Study designs varied between articles: one study was a randomized controlled trial, whereas the remainder were observational cohorts; 14 defined exposure to zidovudine specifically in the first trimester; and 12 had control groups who received other forms of ART ( . There was also some evidence of publication bias according to Egger's test for small study effects, where a small P value indicates asymmetry in the funnel plot (P ¼ 0.04 for overall malformation; P ¼ 0.08 for cardiac malformation; P ¼ 0.26 for male genital malformation).
In the MAX cohort, 824 women were dispensed zidovudine in the first trimester and 1998 were dispensed ART that did not include zidovudine in the first trimester. Before matching, there were some small differences in baseline characteristics between the exposure groups; women with first trimester zidovudine exposures were slightly older, less likely to be black, had deliveries earlier in the study period, had more psychiatric diagnoses and antidepressant use, and were more likely to be dispensed an antiretroviral medication in the 3 months prior to pregnancy ( Table 2 ). The 1 : 1 matching procedure resulted in a sample of 735 women each in the zidovudine and comparator groups. In the matched sample, these differences between baseline characteristics decreased ( Table 2) . Women with first trimester zidovudine exposure who were unmatched, and thus dropped from the analysis, were slightly more likely to receive antiretroviral drugs in the baseline period (59% in unmatched group versus 54% in matched group) and were dispensed more prescriptions overall (mean ¼ 7.34 in unmatched group versus mean ¼ 6.85 in the matched group).
Prior to matching, women with a first trimester dispensing of zidovudine had a 4.6% risk of overall malformations, compared to 4.0% in the comparison group (Table 3) . After implementing the matching procedure, these risks shifted to 4.6 and 4.9%, respectively. In both the full sample and the matched sample, women with first trimester zidovudine exposure and those without had similar risk of cardiac malformations (1.5 versus 1.5% in the full sample; 1.5 versus 1.6% in the matched sample). Among women with first trimester zidovudine exposure, there were no male genital malformations in the full sample.
Zidovudine use in pregnancy Rough et al. 1739 Among infants with first trimester exposure to zidovudine, cardiac malformations were the most common type of malformation. The remainder of malformations were heterogeneous, with no more than five linked to any single organ system. Within the category of cardiac malformations, there was also considerable diversity, including diagnoses of patent ductus arteriosus, right ventricular outflow tract obstruction, left ventricular outflow tract obstruction, secundum atrial septal defects, single ventricle defects, and conotruncal defects.
When comparing ARTwith first trimester zidovudine to ART without first trimester zidovudine, the Bayesian posterior OR estimates were slightly above the null for overall malformation (OR ¼ 1.11; 95% credible interval: 0.80-1.55) and cardiac malformation (OR ¼ 1.30; 95% credible interval: 0.63-2.71). Because there were no exposed cases of male genital malformations in the MAX cohort, the Bayesian model did not converge for that outcome.
For the outcome of overall malformation, restricting the meta-analysis to studies with similar designs to what was implemented in the MAX cohort (i.e. classified zidovudine exposure during the first trimester, required that women in the comparison group received ART, and controlled for confounding) resulted in very similar posterior OR estimates, though the credible interval became wider (OR ¼ 1.08; 95% credible interval: 0.70-1.69). We were unable to conduct similar sensitivity analyses for the cardiac and male genital malformation outcomes because there were a prohibitively small number of studies that met the more restrictive criteria.
Discussion
The use of antiretroviral agents, including zidovudine, has dramatically lowered the risk of perinatal HIV transmission. In a nationwide cohort of Medicaid-enrolled pregnant women with HIV from the years 2000 to 2010, we found that first trimester exposure to zidovudine was relatively common, comprising 30% of deliveries for ART-treated women with HIV. Our systematic review and meta-analysis captured existing information in the literature, which used Bayesian methods to incorporate novel information from Medicaid. Compared to women with ART regimens that did not include zidovudine in the first trimester, those with first-trimester zidovudine exposure had a modest increase in the odds of overall malformation and cardiac malformation, though the 95% credible intervals in the Bayesian analysis included the null value of 1. No exposed cases of male genital malformation were observed in the MAX cohort. However, our metaanalysis of previous studies reporting estimates for this outcome indicate that there may be a substantial increase in risk of male genital malformations for infants with inutero zidovudine exposure, though estimates were imprecise because of the limited sample size and the rare nature of the outcome.
The severity and clinical impact of the specific malformations observed is unclear. In the MAX data, the cardiac malformations identified among infants with first-trimester zidovudine exposure were largely heterogeneous. Studies included in the meta-analysis identified an excess of ventricular septal defects among infants with in-utero zidovudine exposure, and these defects are often managed nonsurgically [40] . A 2015 study in France found that most identified cardiac malformations were minor and less than 10% required a surgical intervention [7] . The male genital malformations identified in previous studies were predominantly hypospadias, which generally has a good prognosis [41] .
Because of the relatively smaller size of MAX compared to the number of women included across all studies in the meta-analysis, posterior credible intervals from the Bayesian analysis were wider than confidence intervals from the meta-analysis alone. In sensitivity analyses, we undertook an alternative analytical approach, treating the MAX data as another entry in the meta-analysis. This led to OR estimates of 1.13 (1.01, 1.27) for overall malformations and 1.53 (1.08, 2.17) for cardiac malformations, which are similar to the findings of the meta-analysis before including the MAX data. Findings from this study must also be interpreted within the context of existing knowledge about the use of zidovudine and other antiretroviral drugs during pregnancy. In addition to potential teratogenicity, many considerations influence treatment decisions for pregnant women with HIV, including treatment availability, tolerability of side-effects, interactions with other medications, drug resistance, and other maternal and infant safety concerns.
An important infant safety concern for zidovudine use in pregnancy is its possible link to mitochondrial dysfunction, a debilitating disorder caused by disturbances in the mitochondrial oxidative phosphorylation system. Animal models have suggested zidovudine causes transplacental mitochondrial toxicity [42] , and studies of mitochondrial function biomarkers have found inverse relationships with in-utero exposure to zidovudine [43] and nucleoside drugs [44] . Epidemiological evidence of zidovudine use during pregnancy leading to mitochondrial dysfunction has been mixed, with some studies supporting the link [45, 46] , but others finding no relationship [47] [48] [49] [50] . We did not examine mitochondrial dysfunction in this study but, alongside malformations, it is a key safety consideration when contemplating the use of zidovudine during pregnancy.
Our study has several limitations. First, it is possible that some children were enrolled in multiple studies, including MAX, which would artificially increase the sample size and decrease the variance. However, we do not expect bias in our estimates because the prospective nature of nearly all included studies makes it unlikely that repeated observations are differential with respect to outcome. Second, classification of exposure to zidovudine during the first trimester was based on an algorithm to estimate LMP. This may result in some nondifferential misclassification of the exposure, which would bias estimates toward the null. Third, we were only able to follow infants for 3 months after delivery, limiting outcome sensitivity, and were not able to review medical records for cases of suspected malformations, limiting outcome specificity. However, a previous validation study showed a good positive predictive value for claims-based definitions of cardiac malformations in MAX [24] . We expect any outcome misclassification to be nondifferential, and therefore biased toward the null. Fourth, the MAX dataset and nearly all studies included in the metaanalysis were observational cohorts, and there is potential for residual confounding. However, this should be limited by use of propensity score matching and an active comparator group. Fifth, because MAX and some studies in the meta-analysis are restricted to only include live births, there is a potential for selection bias if malformations due to first-trimester zidovudine were so severe that pregnancies ended in miscarriage or stillbirth. Finally, the data from MAX and most studies included in the meta-analysis were conducted in highincome countries in North America and Europe. However, most women receiving ART during pregnancy are from low-income countries, and it is unclear how our results may generalize to these settings.
Our study also has multiple strengths. Because exposure was measured through pharmacy dispensing records, our measurements will not be impacted by inconsistencies in recall or memory. In addition, the active comparator design also makes our results clinically interpretable and minimizes the potential for bias because of confounding. Finally, our posterior estimates summarize all currently available information, and are especially useful in this context because of the rare nature of organ-specific malformations.
In conclusion, these findings provide reassurance that for most types of congenital malformations, first-trimester exposure to zidovudine results in minimal differences in risk compared to other treatment strategies. The potential increase in male genital malformations appears small in absolute magnitude, but should continue to be monitored. It will be important to conduct similar analyses to monitor adverse events associated with other antiretroviral agents used during pregnancy, including other nucleoside agents and newer agents from other classes with limited safety data. Owing to the Bayesian approach used, estimates from this study reflect the most comprehensive evidence available on zidovudine and malformations that can be used as a resource for women with HIV, their healthcare providers, and policy makers to assess options for treatment of HIV during pregnancy. K.R., G.R.S., P.L.W., and S.H-D. were the authors who conceived and designed the study. K.R. and J.W.S. conducted the systematic review. K.R. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. K.R. was responsible for conducting statistical analyses, and led the drafting of the manuscript. K.F.H., B.T.B., and S.H-D. provided leadership and oversight of the creation of the MAX pregnancy cohort. All authors provided input on the study design, interpretation of analyses, and revisions to manuscript. 
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